News & blog
SINCLAIR ENDS OFFER PERIOD AFTER “ROBUST” PERFORMANCE
Chester-based pharmaceutical company Sinclair Pharma is ending its offer period after it decided that shareholder prospects are “superior as an independent entity”.
The company said it had conducted a strategic review on the back of securing new deals and enjoying a robust trading performance, and concluded that it is well positioned for significant long-term growth.
As such, it will no longer be in an offer period.
Elsewhere, the manufacturer has signed an exclusive four-year US distribution and strategic marketing agreement with Thermigen LLC for Silhouette InstaLift.
Thermi works in minimally invasive thermistor-regulated energy services for aesthetics, dermatology and women’s health. Silhouette InstaLift is the only injectable aesthetic product with a lifting claim in the US market. Read More
19th May 2016Contractor selected for £18.5m town centre car park